版本:
中国

BRIEF-Abbvie says two phase 3 studies evaluating veliparib did not meet their primary endpoints

April 19 Abbvie Inc:

* Abbvie announces topline results from two phase 3 studies investigating veliparib in combination with chemotherapy for the treatment of patients with advanced or metastatic squamous non-small cell lung cancer and early-stage triple-negative breast cancer

* Abbvie inc - two phase 3 studies evaluating veliparib did not meet their primary endpoints Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐